Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$22.68 0.40 (1.80%)
2/9/2010 4:00 PM

Pharmasset, Inc. (VRUS)

CAPS Rating:
**

A clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating VRUS

Add Stock to Watchlist

What the Community Thinks

Total Members

58 Outperforms
30 Underperforms
 

All-Stars

19 Outperforms
14 Underperforms
 

Wall Street

12 Outperforms
0 Underperforms
 

Members bullish on VRUS are also bullish on:

Members bearish on VRUS are also bearish on:

Ticker Tags

Aggressive Growth (860), Biotechnology (220), IPO in 2007 (211), Defensive (1457), Healthcare (711), Small Cap (1645), Growth (1902), Drug Related Products (7)
Suggest a tag

Pharmasset, Inc. At A Glance

Current Price: $22.68
Last Trade Time: 2/9/2010 4:00 PM
Open: $22.30
Previous Close: $22.28
Daily Range: $22.14 - $23.00
52-Week Range: $7.62 - $24.60
Volume: 210,688
Market Cap: $641.34M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

VRUS VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

2

Pharmasset, Inc. (VRUS)

Avatar TMFBreakerBrian (99.33) Submitted: 3/31/08 1:37 PM

Top HCV polymerase inhibitor on the block right now. Look for combo treatments with the protease inhibitors. Roche is the ideal partner for any anti-HCV drugmaker... Plus a little bit of extra pipeline to boot although not as exciting as its anti-HCV drug.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

4

Pharmasset, Inc. (VRUS)

Avatar majakblue (< 20) Submitted: 1/19/08 12:48 AM

Ridiculous run-up. Typical pharma wannabe IPO. It probably will outperform initially as investors raise the price artificially high, and then tank as it becomes clear that the company will not be profitable for years to come if ever. It would be a good investment if you want to time the market. Ge...More

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 11 :   1 2 3 Next »

Recs

0

 (VRUS)

Avatar zzlangerhans (99.64) Submitted: 11/14/09 7:57 AM : Underperform Start Price: $22.55 VRUS Score: -3.44

A springtime mystery of the low valuation of Pharmasset stock has given way to an autumn enigma of the near triple in share price since May. No one seems to be able to make up their minds about this company. I've tracked them up and down on CAPS but I always seem to bail out of my picks leaving 50% of potential points on the table. The true valuation of Pharmasset stock remains the Schrodinger's cat of baby biotech. While the current share price is still far below the all-time high of 35 seen after the initial encouraging phase I data for R7128, the market cap of 630M isn't way below the high of 740M due to multiple dilutive financings. Strong results for INFORM-1 came after the share price had already tripled and have only served, in my opinion, to delay an inevitable return of the share price to the low teens during the long wait for phase II data for R7128.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VRUS)

Avatar ScreenerStizBear (< 20) Submitted: 6/26/08 2:26 PM : Underperform Start Price: $19.04 VRUS Score: -33.37

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VRUS)

Avatar Rep07 (96.84) Submitted: 6/17/08 11:44 AM : Underperform Start Price: $20.10 VRUS Score: -31.12

Show me why this is worth so much. We're into a bear market so it better be good. Meanwhile ima short this sucka

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (VRUS)

Avatar TMFBreakerBrian (99.33) Submitted: 3/31/08 1:37 PM : Outperform Start Price: $18.01 VRUS Score: 42.05

Top HCV polymerase inhibitor on the block right now. Look for combo treatments with the protease inhibitors. Roche is the ideal partner for any anti-HCV drugmaker... Plus a little bit of extra pipeline to boot although not as exciting as its anti-HCV drug.

Report this Post Replies: 0 | Reply | Permalink

Recs

4

 (VRUS)

Avatar majakblue (< 20) Submitted: 1/19/08 12:48 AM : Underperform Start Price: $29.16 VRUS Score: 10.06

Ridiculous run-up. Typical pharma wannabe IPO. It probably will outperform initially as investors raise the price artificially high, and then tank as it becomes clear that the company will not be profitable for years to come if ever. It would be a good investment if you want to time the market. Get out now! Before it goes plop plop fizz fizz. Whoops, thats another drug company. As for me, I am a geneticist -biochemist who has worked for pharma start-ups, and I think it is safer to invest in the lottery.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 11 :   1 2 3 Next »

Wall Street

Results 1 - 12 of 12  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackRWBaird 87.00 09/09/09 Outperform NS $20.25+12.00%+4.59%+7.41
TrackWedbush 66.12 03/18/09 Outperform NS $9.35+142.57%+40.27%+102.29
TrackThinkEquity 64.82 01/27/09 Outperform NS $10.75+110.98%+29.70%+81.28
TrackCowenandCo 86.76 10/29/08 Outperform NS $16.43+38.04%+17.86%+20.18
TrackLazardCapit < 20 10/21/08 Outperform NS $21.55+5.24%+13.41%-8.17
TrackLeerinkSwan 92.83 07/28/08 Outperform NS $18.58+22.07%-11.85%+33.92
TrackPacificGrow 89.01 05/21/08 Outperform NS $17.74+27.85%-20.39%+48.24
TrackUBS 87.99 04/02/08 Outperform NS $20.00+13.40%-18.99%+32.39
TrackMerriman < 20 03/11/08 Outperform NS $15.60+45.38%-14.52%+59.91
TrackSusquehanna 74.67 12/07/07 Outperform NS $14.15+60.28%-25.81%+86.10
TrackJMP 71.98 06/07/07 Outperform NS $8.90+154.83%-25.21%+180.04
TrackBofASec 94.61 06/06/07 Outperform NS $9.00+152.00%-25.87%+177.87

Results 1 - 12 of 12  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD03 687ms